James R. Gray

2.6k total citations · 1 hit paper
44 papers, 1.4k citations indexed

About

James R. Gray is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, James R. Gray has authored 44 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 14 papers in Surgery and 10 papers in Oncology. Recurrent topics in James R. Gray's work include Gastrointestinal motility and disorders (6 papers), Prostate Cancer Diagnosis and Treatment (6 papers) and Gastric Cancer Management and Outcomes (6 papers). James R. Gray is often cited by papers focused on Gastrointestinal motility and disorders (6 papers), Prostate Cancer Diagnosis and Treatment (6 papers) and Gastric Cancer Management and Outcomes (6 papers). James R. Gray collaborates with scholars based in United States, Canada and United Kingdom. James R. Gray's co-authors include Beryl McCormick, Louise Cox, Joachim Yahalom, John D. Hainsworth, F. Anthony Greco, Pierre Paré, Howard A. Burris, Robert Balshaw, Suzanne M. Kelly and Christopher R. McBurney and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

James R. Gray

43 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Does age matter? The impact of rodent age on study outcomes

2016 249 citations James R. Gray et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James R. Gray United States	20	465	372	266	234	216	44	1.4k
Marcel J. R. Janssen Netherlands	21	427 0.9×	435 1.2×	129 0.5×	126 0.5×	103 0.5×	59	1.6k
M. Lise Italy	27	1.2k 2.5×	456 1.2×	240 0.9×	684 2.9×	284 1.3×	116	2.3k
Michael Sørensen Denmark	32	1.3k 2.7×	126 0.3×	95 0.4×	361 1.5×	274 1.3×	122	2.8k
Gianluigi Lunardi Italy	25	189 0.4×	408 1.1×	38 0.1×	801 3.4×	317 1.5×	68	1.9k
Suren Soghomonyan United States	17	322 0.7×	189 0.5×	97 0.4×	259 1.1×	519 2.4×	48	1.5k
Nobuhiko Oridate Japan	32	990 2.1×	678 1.8×	158 0.6×	711 3.0×	1.1k 5.1×	208	3.1k
Tarun Singhal United States	20	336 0.7×	183 0.5×	36 0.1×	78 0.3×	144 0.7×	72	1.4k
Justin Geoghegan Ireland	25	767 1.6×	373 1.0×	88 0.3×	708 3.0×	280 1.3×	90	2.6k
Kazumasa Torimoto Japan	22	650 1.4×	427 1.1×	15 0.1×	295 1.3×	280 1.3×	157	1.9k
Kyu Joo Park South Korea	22	275 0.6×	304 0.8×	180 0.7×	715 3.1×	477 2.2×	44	1.4k

Countries citing papers authored by James R. Gray

Since Specialization

Citations

This map shows the geographic impact of James R. Gray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Gray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Gray more than expected).

Fields of papers citing papers by James R. Gray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James R. Gray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Gray. The network helps show where James R. Gray may publish in the future.

Co-authorship network of co-authors of James R. Gray

This figure shows the co-authorship network connecting the top 25 collaborators of James R. Gray. A scholar is included among the top collaborators of James R. Gray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James R. Gray. James R. Gray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Bhinder, Ganive, et al.. (2023). Irritable Bowel Syndrome Patient Experience: A Survey of Patient-Reported Symptoms by Irritable Bowel Syndrome Subtype and Impact on Quality of Life. Journal of the Canadian Association of Gastroenterology. 6(6). 219–228. 4 indexed citations

2.

Wang, Kyle, Ronald C. Chen, Clinton A. Medbery, et al.. (2018). Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial. International Journal of Radiation Oncology*Biology*Physics. 102(5). 1430–1437. 22 indexed citations

3.

Fuller, Donald B., Aaron D. Falchook, Tami Crabtree, et al.. (2018). Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes. European Urology Oncology. 1(6). 540–547. 44 indexed citations

4.

Fuller, Donald B., Clinton A. Medbery, Kelly Underhill, et al.. (2017). 5-year outcomes from a prospective multi-institutional trial of heterogeneous dosing stereotactic body radiotherapy (SBRT) for low- and intermediate-risk prostate cancer.. Journal of Clinical Oncology. 35(6_suppl). 35–35. 5 indexed citations

5.

Taylor, S., Emmanuel H. Demont, James R. Gray, et al.. (2015). Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P ₁ Agonists. Journal of Medicinal Chemistry. 58(20). 8236–8256. 13 indexed citations

6.

Taylor, S., James R. Gray, Robert Willis, et al.. (2012). The utility of pharmacokinetic–pharmacodynamic modeling in the discovery and optimization of selective S1P₁agonists. Xenobiotica. 42(7). 671–686. 4 indexed citations

7.

Brahmania, Mayur, et al.. (2012). Clinical and Endoscopic Significance of Bowel-Wall Thickening Reported on Abdominal Computed Tomographies in Symptomatic Patients with No History of Gastrointestinal Disease. Canadian Association of Radiologists Journal. 65(1). 67–70. 27 indexed citations

8.

Prestidge, Bradley R., William S. Bice, Brian J. Moran, et al.. (2011). Five-Year Biochemical Control Following Cesium-131 Permanent Prostate Brachytherapy in a Multi-institutional Trial. Brachytherapy. 10. S27–S28. 2 indexed citations

9.

Greco, F. Anthony, David R. Spigel, Dianna Shipley, et al.. (2007). Paclitaxel/Carboplatin/Gemcitabine Versus Gemcitabine/Vinorelbine in Advanced Non–Small-Cell Lung Cancer: A Phase II/III Study of the Minnie Pearl Cancer Research Network. Clinical Lung Cancer. 8(8). 483–487. 11 indexed citations

10.

Paré, Pierre, Ronald Bridges, M C Champion, et al.. (2007). Recommendations on Chronic Constipation (including Constipation Associated with Irritable Bowel Syndrome) Treatment. Canadian Journal of Gastroenterology. 21(suppl b). 3B–22B. 17 indexed citations

11.

Paré, Pierre, James R. Gray, Robert Balshaw, et al.. (2006). Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: Baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study. Clinical Therapeutics. 28(10). 1726–1735. 157 indexed citations

12.

Hainsworth, John D., James R. Gray, Sharlene Litchy, et al.. (2004). A Phase II Trial of Preoperative Concurrent Radiation Therapy and Weekly Paclitaxel/Carboplatin for Patients with Locally Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 6(1). 33–42. 9 indexed citations

13.

Meluch, Anthony A., F. Anthony Greco, James R. Gray, et al.. (2003). Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5-FU and Radiation Therapy in Locoregional Esophageal Cancer. The Cancer Journal. 9(4). 251–260. 92 indexed citations

14.

Hainsworth, John D., Lisa H. Morrissey, Daniel C. Scullin, et al.. (2002). Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma. Cancer. 94(9). 2426–2433. 7 indexed citations

15.

Hainsworth, John D., Lisa H. Morrissey, Daniel C. Scullin, et al.. (2002). Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma. Cancer. 94(9). 2426–2433. 25 indexed citations

16.

Hainsworth, John D., Anthony A. Meluch, James R. Gray, et al.. (2002). Induction Paclitaxel, Carboplatin, and Infusional 5-FU Followed by Concurrent Radiation Therapy and Weekly Paclitaxel/Carboplatin in the Treatment of Locally Advanced Head and Neck Cancer. The Cancer Journal. 8(4). 311–321. 36 indexed citations

17.

Greco, F. Anthony, Howard A. Burris, James R. Gray, et al.. (2001). Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma. Cancer. 92(8). 2142–2147. 7 indexed citations

18.

Greco, Frank A., Howard A. Burris, James R. Gray, et al.. (2000). Carcinoma of unknown primary site. Cancer. 89(12). 2655–2660. 59 indexed citations

19.

Gray, James R., et al.. (2000). In vivo enhancement of chemotherapy with static electric or magnetic fields. Bioelectromagnetics. 21(8). 575–583. 59 indexed citations

20.

Gray, James R. & Kent E. Wallner. (1990). Reversal of cranial nerve dysfunction with radiation therapy in adults with lymphoma and leukemia. International Journal of Radiation Oncology*Biology*Physics. 19(2). 439–444. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact